Tissue Engineering seminars

Brain organoids and other non-animal models offer ways to investigate brain development and disease and evaluate candidate therapies. Their wider use depends on addressing variability in organoid generation, reagents, culture conditions and analysis, alongside the demands of complex workflows when increasing experimental throughput. Ali Strtak and Fikri Birey discuss how to improve consistency between organoids and experiments. The session examines reagent and vendor variation, ways to simplify multistep procedures, suitable controls and analytical methods, and emerging culture, automation and analysis technologies. It considers how these approaches can make brain-organoid research more reproducible, standardized and scalable, followed by a live question-and-answer discussion.

Tatsuya Osaki examines vascular contributions to autism spectrum disorder, focusing on blood–brain barrier integrity and cerebral blood-flow dynamics during early development. Rett syndrome provides a starting point: MeCP2 mutations impair endothelial function, suggesting that vascular cells themselves contribute to disease mechanisms. A three-dimensional microphysiological model built from human induced pluripotent stem cells recreates blood–brain barrier structure and function. Patient-derived endothelial cells form perfusable microvascular networks but show impaired barrier function, a finding independently corroborated in MeCP2-knockout mice. Transcriptomic analyses implicate increased miR-126 expression and disrupted tight junctions; inhibiting miR-126-3p restores barrier function and identifies a potential therapeutic target. The work is extending to hemodynamic changes in other autism subtypes, with two-photon imaging providing in-vivo cross-validation, to identify shared neurovascular mechanisms and candidate interventions.

Yun Xia presents macrophage–kidney assembloids that address missing immune and vascular components in stem-cell organoids. Directed differentiation, self-organization, genetic perturbation, xenotransplantation and single-cell analysis reveal immune–epithelial interactions. Macrophages from the same parental cells acquire resident phenotypes; diabetic and polycystic kidney models show context-dependent effects on inflammation, epithelial injury and disease progression. Minoru Takasato addresses kidney organoids’ missing urinary outflow by generating bladder tissue from human pluripotent cells. Stepwise differentiation passes through endoderm, hindgut and cloaca; FGF4 posteriorization and growth-factor screening promote urothelial identity. The resulting sacs contain stratified urothelial cell types, stretch and form a barrier, supporting developmental, disease and future therapeutic studies. Online via Zoom. Tuesday 13 October, 11:00–12:30 SGT (Asia/Singapore). Both talks share this session; individual start times are unspecified. Register through the organizer page. Professional, trainee or student status in stem cells, regenerative medicine or an adjacent field is required; organizer approval and recording restrictions apply.

Astrocytes help sustain neural signaling and tissue stability, but injury and implanted devices cause them to change their functions. Tim O'Shea examines how the extent and timing of this response determine tissue protection, regeneration and implant durability. Limited renewal of adult astrocytes contrasts with the greater proliferation and migration of immature cells in newborn mammals. Around implants, continuing movement, infection and other stimuli can prolong the response and affect device performance. The talk uses astrocyte-specific transcriptomic assays to investigate this reprogramming and considers how to improve repair without sacrificing normal astrocyte functions. It also presents biomaterial and cell-transplant approaches being studied in preclinical stroke, spinal cord injury and implant-response models.

UCL Department of Neuroinflammation Seminar by Professor Emad Moeendarbary (Professor of Cell Mechanics and Mechanobiology, UCL Mechanical Engineering) on how biophysical factors such as substrate stiffness and axon geometry regulate oligodendrocyte behavior and myelin formation, presenting the AxoMetic in vitro myelination platform for discovery of remyelinating therapies.

This English-language webinar examines advances in organoid research, production, and drug discovery. Hideya Sakaguchi covers the developmental-biology origins of neural organoid research and its potential for drug discovery, followed by a keynote from Thomas Mitchell of The Organoid Company and a live question session.

The human brain sets us apart as a species, with its size being one of its most striking features. Brain size is largely determined during development as vast numbers of neurons and supportive glia are generated. In an effort to better understand the events that determine the human brain’s cellular makeup, and its size, we use a human model system in a dish, called cerebral organoids. These 3D tissues are generated from pluripotent stem cells through neural differentiation and a supportive 3D microenvironment to generate organoids with the same tissue architecture as the early human fetal brain. Such organoids are allowing us to tackle questions previously impossible with more traditional approaches. Indeed, our recent findings provide insight into regulation of brain size and neuron number across ape species, identifying key stages of early neural stem cell expansion that set up a larger starting cell number to enable the production of increased numbers of neurons. We are also investigating the role of extrinsic regulators in determining numbers and types of neurons produced in the human cerebral cortex. Overall, our findings are pointing to key, human-specific aspects of brain development and function, that have important implications for neurological disease.

The human gut microbiome has emerged as a key player in the bidirectional communication of the gut-brain axis, affecting various aspects of homeostasis and pathophysiology. Until recently, the majority of studies that seek to explore the mechanisms underlying the microbiome-gut-brain axis cross-talk relied almost exclusively on animal models, and particularly gnotobiotic mice. Despite the great progress made with these models, various limitations, including ethical considerations and interspecies differences that limit the translatability of data to human systems, pushed researchers to seek for alternatives. Over the past decades, the field of in vitro modelling of tissues has experienced tremendous growth, thanks to advances in 3D cell biology, materials, science and bioengineering, pushing further the borders of our ability to more faithfully emulate the in vivo situation. Organ-on-chip technology and bioengineered tissues have emerged as highly promising alternatives to animal models for a wide range of applications. In this talk I’ll discuss our progress towards generating a complete platform of the human microbiota-gut-brain axis with integrated monitoring and sensing capabilities. Bringing together principles of materials science, tissue engineering, 3D cell biology and bioelectronics, we are building advanced models of the GI and the BBB /NVU, with real-time and label-free monitoring units adapted in the model architecture, towards a robust and more physiologically relevant human in vitro model, aiming to i) elucidate the role of microbiota in the gut-brain axis communication, ii) to study how diet and impaired microbiota profiles affect various (patho-)physiologies, and iii) to test personalised medicine approaches for disease modelling and drug testing.

Reprogramming somatic cells to a pluripotent state via the induced pluripotent stem cell (iPSC) method offers an increasingly utilized approach for neurological disease modeling with patient-derived cells. Several groups, including ours, have applied the iPSC approach to model severe genetic developmental and epileptic encephalopathies (DEEs) with patient-derived cells. Although most studies to date involve 2-D cultures of patient-derived neurons, brain organoids are increasingly being employed to explore genetic DEE mechanisms. We are applying this approach to understand PMSE (Polyhydramnios, Megalencephaly and Symptomatic Epilepsy) syndrome, Rett Syndrome (in collaboration with Ben Novitch at UCLA) and Protocadherin-19 Clustering Epilepsy (PCE). I will describe our findings of robust structural phenotypes in PMSE and PCE patient-derived brain organoid models, as well as functional abnormalities identified in fusion organoid models of Rett syndrome. In addition to showing epilepsy-relevant phenotypes, both 2D and brain organoid cultures offer platforms to identify novel therapies. We will also discuss challenges and recent advances in the brain organoid field, including a new single rosette brain organoid model that we have developed. The field is advancing rapidly and our findings suggest that brain organoid approaches offers great promise for modeling genetic neurodevelopmental epilepsies and identifying precision therapies.

While the motion and collective behavior of cells are well-studied on flat surfaces or in unconfined liquid media, in most natural settings, cells thrive in complex 3D environments. Bioprinting processes are capable of structuring cells in 3D and conventional bioprinting approaches address this challenge by embedding cells in bio-degradable polymer networks. However, heterogeneity in network structure and biodegradation often preclude quantitative studies of cell behavior in specified 3D architectures. Here, I will present a new approach to 3D bioprinting of cellular communities that utilizes jammed, granular polyelectrolyte microgels as a support medium. The self-healing nature of this medium allows the creation of highly precise cellular communities and tissue-like structures by direct injection of cells inside the 3D medium. Further, the transparent nature of this medium enables precise characterization of cellular behavior. I will describe two examples of my work using this platform to study the behavior of two different classes of cells in 3D. First, I will describe how we interrogate the growth, viability, and migration of mammalian cells—ranging from epithelial cells, cancer cells, and T cells—in the 3D pore space. Second, I will describe how we interrogate the migration of E. coli bacteria through the 3D pore space. Direct visualization enables us to reveal a new mode of motility exhibited by individual cells, in stark contrast to the paradigm of run-and-tumble motility, in which cells are intermittently and transiently trapped as they navigate the pore space; further, analysis of these dynamics enables prediction of single-cell transport over large length and time scales. Moreover, we show that concentrated populations of E. coli can collectively migrate through a porous medium—despite being strongly confined—by chemotactically “surfing” a self-generated nutrient gradient. Together, these studies highlight how the jammed microgel medium provides a powerful platform to design and interrogate complex cellular communities in 3D—with implications for tissue engineering, microtissue mechanics, studies of cellular interactions, and biophysical studies of active matter.

A key question for basic biology and regenerative medicine concerns the way in which evolution exploits physics toward adaptive form and function. While genomes specify the molecular hardware of cells, what algorithms enable cellular collectives to reliably build specific, complex, target morphologies? Our lab studies the way in which all cells, not just neurons, communicate as electrical networks that enable scaling of single-cell properties into collective intelligences that solve problems in anatomical feature space. By learning to read, interpret, and write bioelectrical information in vivo, we have identified some novel controls of growth and form that enable incredible plasticity and robustness in anatomical homeostasis. In this talk, I will describe the fundamental knowledge gaps with respect to anatomical plasticity and pattern control beyond emergence, and discuss our efforts to understand large-scale morphological control circuits. I will show examples in embryogenesis, regeneration, cancer, and synthetic living machines. I will also discuss the implications of this work for not only regenerative medicine, but also for fundamental understanding of the origin of bodyplans and the relationship between genomes and functional anatomy.

A variety of pharmacological treatments exist for patients suffering from focal seizures, but systemically administered drugs offer only symptomatic relief and frequently cause unwanted side effects. Moreover, available drugs are ineffective in one third of the patients. Thus, developing more targeted and effective treatment strategies is highly warranted. Neurotrophic factors are candidates for treating epilepsy, but their development has been hampered by difficulties in achieving stable and targeted delivery of efficacious concentrations within the brain. We have developed an implantable cell encapsulation system that delivers high and consistent levels of neurotrophic molecules directly to a specific brain region. The potential of this approach has been tested by delivering glial cell line-derived neurotrophic factor (GDNF) to the hippocampus of epileptic rats. In vivo studies demonstrated that these intrahippocampal implants continue to secrete GDNF and produce high hippocampal GDNF tissue levels in a long-lasting manner. Identical implants rapidly and greatly reduced seizure frequency in the pilocarpine model. This effect increased in magnitude over 3 months, ultimately leading to a reduction of spontaneous seizures by more than 90%. Importantly, these effects were accompanied by improvements in cognition and anxiety, and by the normalization of many histological alterations that are associated with chronic epilepsy. In addition, the antiseizure effect persisted even after device removal. Finally, by establishing a unilateral epileptic focus using the intrahippocampal kainate model, we found that delivery of GDNF exclusively within the focus suppressed already established spontaneous recurrent seizures. Together, these results support the concept that the implantation of encapsulated GDNF-secreting cells can deliver GDNF in a sustained, targeted, and efficacious manner. These findings may form the basis for clinical translation of this approach.